Your browser doesn't support javascript.
loading
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle, Rémy; Bachet, Jean-Baptiste; Harlé, Alexandre; Iovanna, Juan; Hammel, Pascal; Rebours, Vinciane; Turpin, Anthony; Ben Abdelghani, Meher; Wei, Alice; Mitry, Emmanuel; Lopez, Anthony; Biagi, James; François, Eric; Artru, Pascal; Lambert, Aurélien; Renouf, Daniel J; Monard, Laure; Mauduit, Marjorie; Dusetti, Nelson; Conroy, Thierry; Cros, Jérome.
Afiliação
  • Nicolle R; Université Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018, Paris, France.
  • Bachet JB; Service d'Hépato-Gastro-Entérologie, Hôpital Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Sorbonne Université, Paris, France.
  • Harlé A; Service de Biopathologie, Institut de Cancérologie de Lorraine, Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy CEDEX, France.
  • Iovanna J; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille Université and Institut Paoli-Calmettes; Parc Scientifique et Technologique de Luminy, Marseille, France.
  • Hammel P; Digestive and Medical Oncology, Paul Brousse Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université of Paris Saclay, Villejuif, France.
  • Rebours V; Université Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM, U1149, CNRS, ERL 8252, F-75018, Paris, France.
  • Turpin A; Pancreatology and Digestive Oncology Department, Beaujon Hospital, APHP, Clichy and Centre de Référence des Maladies Rares du Pancréas-PAncreaticRaresDISeases (PaRaDis), Paris, France.
  • Ben Abdelghani M; Department of Oncology, Lille University Hospital; CNRS UMR9020, INSERM UMR1277, University of Lille, Institut Pasteur, Lille, France.
  • Wei A; Institut de Cancérologie Strasbourg Europe, Strasbourg, France.
  • Mitry E; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Lopez A; Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
  • Biagi J; Hepatogastroenterology Department, University Hospital, Nancy, France.
  • François E; Department of Oncology, Queen's University, Kingston, Canada.
  • Artru P; Hepatogastroenterology department, Hôpital Jean-Mermoz, Lyon, France.
  • Lambert A; Medical Oncology department, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
  • Renouf DJ; Université de Lorraine, APEMAC, équipe MICS, Nancy, France.
  • Monard L; Medical Oncology department, Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
  • Mauduit M; Université de Lorraine, APEMAC, équipe MICS, Nancy, France.
  • Dusetti N; Division of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Conroy T; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Cros J; R&D Unicancer, Paris, France.
J Clin Oncol ; 42(9): 1067-1076, 2024 Mar 20.
Article em En | MEDLINE | ID: mdl-37963313
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article